Practical, legal, and ethical issues in expanded access to investigational drugs

New England Journal of Medicine

Volumn 372, Issue 3, 2015, Pages 279-286

  Darrow, Jonathan J ^a   Sarpatwari, Ameet ^a   Avorn, Jerry ^a   Kesselheim, Aaron S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPASSIONATE USE; COOPERATION; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG PROGRAM; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; INDUSTRY PARTICIPATION; JURISPRUDENCE; LAW; LEGAL ASPECT; LEGAL LIABILITY; MEDICAL ETHICS; PATIENT RIGHT; PROFESSIONAL KNOWLEDGE; REVIEW; BIOETHICS; ETHICS; HEALTH CARE DELIVERY; HISTORY; LEGISLATION AND JURISPRUDENCE; UNITED STATES;

NEW DRUG;

BIOETHICAL ISSUES; DRUG APPROVAL; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; GOVERNMENT REGULATION; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84920973014     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMhle1409465     Document Type: Article

References (63)

1. 21 U. S. C. § 355.
2. Pub. L. No. 87-781, 76 Stat. 780 (1962) (codified at 21 U. S. C. § 301 et seq.).
3. Cohen E. Company denies drug to dying child. CNN. com. March 11, 2014 (http://www. cnn. com/2014/03/10/health/ cohen-josh).
4. Herper M. Company makes drug available to ailing boy following public outcry. Forbes. com. March 11, 2014 (http://www. forbes. com/sites/matthewherper/2014/03/11/drug-company-to-make-medicine-available-to-boy-following-public-outcry).
5. Sanghavi D. The pharmaceutical Hail Mary. New York Times Magazine. November 3, 2013:MM40.
6. Roberts BS, Bodenheimer DZ. The drug amendments of 1962: the anatomy of a regulatory failure. Arizona State Law Journal 1982:581-614.
7. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther 2011;89:183-8.
8. FDA drug approval -A lengthy process that delays the availability of important new drugs. Washington, DC: Government Accountability Office, 1980.
9. Investigational new drug, antibiotic, and biologic drug product regulations: treatment use and sale. Fed Regist 1987;52:19466.
10. Expanded access to investigational drugs for treatment use: final rule. Fed Regist 2009;74:40900-45.
11. 21 C. F. R. § 312. 305.
12. 21 C. F. R. § 312. 310.
13. 21 C. F. R. § 312. 315.
14. 21 C. F. R. § 312. 320.
15. Okie S. Access before approval -A right to take experimental drugs? N Engl J Med 2006;355:437-40.
16. Silverman E. The FDA says it's more compassionate than you think. Wall Street Journal. May 5, 2014 (http://blogs. wsj. com/corporate-intelligence/2014/05/05/the-fda-says-its-more-compassionate-than-you-think/).
17. Expanded access to investigational drugs for treatment use. Fed Regist 2006;71:75148.
18. Gaffney A. Regulatory explainer: FDA's expanded access (compassionate use) program. RAPS. org. March 27, 2014 (http:// www. raps. org/regulatoryDetail. aspx?id+AD0-18343).
19. Clinicaltrials. gov home page (https://clinicaltrials. gov).
20. Kroll D. Why everyone has a stake in the Chimerix drug offered to Josh Hardy. Forbes. com. March 12, 2014 (http://www. forbes. com/sites/davidkroll).
21. 21 C. F. R. § 312. 8(d).
22. How much should hepatitis C treatment cost? New York Times. March 16, 2014:SR10.
23. Herper M. The world's most expensive drugs. Forbes. com. February 22, 2010 (http://www. forbes. com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html).
24. Mack GS. Expanded access rules pose quandary for drug developers. Nat Biotechnol 2009;27:871-2.
25. Arnst C. Dying patients fight the FDA. Business Week Online. July 26, 2007 (http://www. businessweek. com/stories/2007-07-25/ dying-patients-fight-the-fdabusinessweek-business-news-stock-market-and-financial-advice).
26. Dooren JC. Connecting patients with experimental drugs. Wall Street Journal. October 22, 2012 (http://www. wsj. com/ articles/SB10000872396390444592704578062640104322714).
27. Hayes E. Access to investigational drugs remains challenge despite new FDA rules. Pink Sheet. March 29, 2010:31.
28. Proposed new drug, antibiotic, and biologic drug product regulations. Fed Regist 1983;48:26729.
29. Dockser Marcus A. Researchers fret as social media lift veil on drug trials. Wall Street Journal. July 29, 2014 (http://online. wsj. com/articles/researchers-fret-as-social-media-lift-veil-on-drug-trials-1406687404).
30. 45 C. F. R. § 46. 116(a)(8).
31. McDiarmid J. Cobourg patient drew the 'short straw' in cancer drug trial. Toronto Star. February 7, 2014 (http://www. thestar. com/news/gta/2014/02/07/cobourg-woman-34-faces-death- from-melanoma-without-access-to-trial-drug.html).
32. Groopman J. The right to a trial: should dying patients have access to experimental drugs? The New Yorker. December 18, 2006:40-7 (http://www. newyorker. com/magazine/2006/12/18/the-right-to-a-trial).
33. Tansey B. The dilemma of a dying man. San Francisco Chronicle. February 16, 2003 (http://www. sfgate. com/business/ article/The-dilemma-of-a-dying-man-Patient-sues-toget-2669983. php).
34. Falit BP, Gross CP. Access to experimental drugs for terminally ill patients. JAMA 2008;300:2793-5.
35. Duke University School of Medicine. Fees. (http://irb. duhs. duke. edu/modules/irb-fees/index. php?id+AD0-1).
36. Columbia University Medical Center Institutional Review Board. IRB fee schedule (http://cumc. columbia. edu/dept/irb/ policies/documents/IRBRateSheets. August12008. pdf).
37. United States v. Rutherford, 442 U. S. 544 (1979).
38. Abigail Alliance v. von Eschenbach, 495 F. 3d 695 (D. C. Cir. 2007).
39. Dahl v. HEM Pharms, 7 F. 3d 1399 (9th Cir. 1993).
40. Cacchillo v. Insmed, 638 F. 3d 401 (2d Cir. 2011).
41. Gunvalson v. PTC Therapeutics, 303 Fed. App'x 128 (3d Cir. 2008).
42. Mello MM, Joffe S. Compact versus contract - industry sponsors' obligations to their research subjects. N Engl J Med 2007;356:2737-43.
43. Dennis B, Cha AE. +ACY-quot;Right to try+ACY-quot; laws spur debate over dying patients' access to experimental drugs. Washington Post. May 16, 2014 (http://www. washingtonpost. com/national/ health-science/right-to-try-laws-spur-debate-over-dyingpatients-access-to-experimental-drugs/2014/05/16/820e08c8-dcfa-11e3-b745-87d39690c5c0-story.html).
44. H. R. 1281, Gen. Assemb., Reg. Sess. (Colo. 2014).
45. H. R. 1685, Gen. Assemb., Reg. Sess. (Mo. 2014).
46. H. R. 891, Gen. Assemb., Reg. Sess. (La. 2014).
47. 21 C. F. R. § 1301. 36.
48. 21 U. S. C. § 823.
49. Mutual Pharmaceutical v. Bartlett, 133 S. Ct. 2466 (2013).
50. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase I oncology trials. N Engl J Med 2005;352:895-904.
51. Freireich EJ, Kurzrock R. The role of investigational therapy in management of patients with advanced metastatic malignancy. J Clin Oncol 2009;27:304-6.
52. Health literacy: a prescription to end confusion. Washington, DC: Institute of Medicine, 2004.
53. Woloshin S, Schwartz LM, Welch HG. Patients and medical statistics: interest, confidence, and ability. J Gen Intern Med 2005;20:996-1000.
54. Kolva E, Rosenfeld B, Brescia R, Comfort C. Assessing decision-making capacity at end of life. Gen Hosp Psychiatry 2014; 36:392-7.
55. Annas GJ. Cancer and the Constitution - choice at life's end. N Engl J Med 2007;357:408-13.
56. 42 C. F. R. § 411. 15(k).
57. Black L. Experimental breast cancer treatments and health insurance coverage. Virtual Mentor 2007;9:34-7.
58. Leonard EW. Right to experimental treatment: FDA new drug approval, constitutional rights, and the public's health. J Law Med Ethics 2009;37:269-79.
59. Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS. Regulatory review of novel therapeutics - comparison of three regulatory agencies. N Engl J Med 2012; 366:2284-93.
60. Darrow JJ, Avorn J, Kesselheim AS. New FDA breakthroughdrug category - implications for patients. N Engl J Med 2014; 370:1252-8.
61. Erratum, N Engl J Med 2014;371:94.
62. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
63. Guidance for industry: expanded access to investigational drugs for treatment use - Qs +ACY-amp;As. Rockville, MD: Food and Drug Administration, 2013 (http://www. fda. gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm351261. pdf).